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Lipid accumulation product in 
relation to 10-year cardiovascular 
disease incidence in Caucasian 
adults; the ATTICA Study
The ATTICA epidemiological cohort study
3042 adults without pre-existing CVD, from the Greek general 
population, aged 18 -89 years, 1514 men
LAP values at baseline were calculated using WC (cm) and TG (mmol/l) values; 
(i) LAP for men= [WC (cm) - 65] x [TG concentration (mmol/L)]; and (ii) LAP for 
women= [WC (cm) - 58] x [TG concentration (mmol/L)]. 
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Incidence of Cardiovascular Disease
2583 of the 3042 initial 
participants were re-assessed 
during this follow-up
An independent positive association 
between LAP and long-term CVD 
incidence in CVD-free Caucasian 
adults from the general population 
was revealed.
LAP was positively associated with with 10-year CVD incidence,
even after adjusting for hypertension, diabetes,
hypercholesterolemia, smoking, physical activity, Mediterranean diet
adherence, and key pro-inflammatory biomarkers (Hazard Ratios per
10 cm⋅mmol/L of LAP ranging from 1.1 to 1.21, p=0.04).
LAP predicted CVD risk better than common obesity indices (BMI, WC,
waist-to-hip, waist-to-height ratio).
LAP is considered to 
expand on the concept of 
the hypertriglyceridemic
waist as regards C VD risk
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Abstract 
Background and aims: The lipid accumulation product (LAP) is an index describing lipid 
over-accumulation based on waist circumference (WC) and fasting triglycerides, and can 
outperform the body mass index (BMI) in recognizing cardiovascular disease (CVD) risk. 
We aimed to explore the association of LAP with long-term CVD risk and compare its CVD-
predictive value against common anthropometric indices/ratios of obesity.  
Methods: ATTICA is a prospective, population-based cohort that recruited 3042 adults 
without pre-existing CVD from the Greek general population (age 18 -89 years; 1514 men). 
The 10-year study follow-up (2011-2012) captured the fatal/non-fatal CVD incidence in 2020 
participants (50% men). Baseline LAP (cm⋅mmol/L) was calculated and analyzed in relation 
to the 10-year CVD incidence.  
Results: In total, 317 CVD cases (15.7%) were documented during the follow-up. Baseline 
LAP showed a significant positive association with the 10-year CVD incidence, even after 
adjusting for hypertension, diabetes, hypercholesterolemia, smoking, physical activity, 
Mediterranean diet adherence, and key pro-inflammatory biomarkers (Hazard Ratios per 10 
cm⋅mmol/L of LAP ranging from 1.1 to 1.21, p=0.04). Moreover, LAP predicted the 10-year 
CVD study incidence better than common obesity indices (BMI, WC, waist-to-hip, waist-to-
height ratio).  
Conclusions: These findings support an independent positive association between LAP and 
long-term CVD incidence in CVD-free Caucasian adults from the general population.  
Key words: Lipid accumulation product, LAP, cardiovascular disease, CVD risk, ATTICA 
study 
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1. Introduction 
Obesity, particularly central (abdominal/visceral), is a key risk factor of cardiovascular 
disease (CVD), with the abdominal fat mass playing a critical role in this relationship [1-3]. 
However, the body mass index (BMI), which is used to categorize obesity in clinical practice 
[4], fails to differentiate between lean and total fat mass, let alone it accounts for the 
abdominal fat mass [3-5]. As such, BMI has been shown to be a crude predictor of CVD risk 
[5-7], whilst other surrogate markers of central obesity, such as waist circumference (WC), 
waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR), are now used in clinical practice 
and/or epidemiological research as better CVD predictors [3,5-8].  
In 2005, using data from the third National Health and Nutrition Examination Survey 
(NHANES III), Henry Kahn proposed the calculation of the lipid accumulation product 
(LAP) based on WC (cm) and fasting serum triglycerides (TG; mmol/L) [LAP in men: (WC-
65) × TG; LAP in women: (WC-58) × TG] [9]. LAP was proposed as a better continuous 
marker/index to describe lipid over-accumulation in relationship to central obesity, and was 
shown to outperform BMI for identifying CVD risk [9]. Indeed, in this NHANES cohort, 
LAP exhibited better correlations with key CVD risk factors (i.e., heart rate and circulating 
levels of lipids and uric acid) compared to BMI [9]. Subsequently, LAP has been reported as 
a reliable marker of CVD risk in women with polycystic ovary syndrome (PCOS) and a 
useful index for recognizing insulin resistance, non-alcoholic fatty liver (NAFLD) and 
metabolic syndrome in various cohorts [10-16]. 
To date, the existing epidemiological data from prospective, community-based studies 
on the predictive value of LAP for long-term CVD risk are very limited [17,18]. Therefore, 
the objective of the present work was to assess LAP as a predictor of the 10-year CVD 
incidence in the ATTICA study cohort of Caucasian adults without previous CVD, and 
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compare its discriminating ability against BMI and other commonly used anthropometric 
indices/ratios of central obesity (i.e., WC, WHR and WHtR). 
 
2. Materials and methods 
2.1 Study sample 
In brief, ATTICA is a prospective, population-based, cohort study performed in Attica 
(Athens metropolitan region, Greece), which recruited 3042 non-institutionalized adults 
(Caucasians; women/men: 1528/1514; age: ≥18 years) without previous CVD. Recruitment 
was conducted during 2001-2002, applying a random sampling protocol and selecting a 
single participant per household. All participants underwent detailed baseline assessments 
which included medical history, physical examination and blood sampling for biochemical 
measurements. Baseline CVD was excluded in all participants by the study physicians. The 
ATTICA study was approved by our Institutional Ethics Committee and conformed to the 
ethical guidelines of the 1975 Declaration of Helsinki, with all participants providing written 
informed consent. The methodology details of the ATTICA study have been previously 
described [19].  
2.2 Baseline study assessments  
Comprehensive baseline data were collected, including demographic details (e.g., age, 
gender and years of education), personal/family history of cardio-metabolic disease (e.g., 
hypertension, diabetes, hypercholesterolemia and CVD), and information about dietary and 
pertinent lifestyle habits (e.g., physical activity and smoking in pack years), as described 
previously [19]. Briefly, all participants underwent a detailed baseline dietary evaluation 
through the EPIC-Greek questionnaire [20], which is a validated semi-quantitative food-
frequency questionnaire that was kindly provided by the Unit of Nutrition of Athens Medical 
School. Moreover, the MedDietScore was used to assess the adherence to the Mediterranean 
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diet (score range: 0-55; higher values indicate better adherence) [21]. The physical activity 
level of each participant was also assessed at baseline using the International Physical 
Activity Questionnaire (IPAQ; participants reporting no physical activities or exercise on the 
IPAQ were classified as physically inactive) [22].  
Standardized measurements were performed by trained study researchers at baseline 
examination, including body weight and height, as well as WC and hip circumference in 
order to calculate the BMI (body weight in kilograms divided by the height in meters 
squared; kg/m2), WHR and WHtR. Furthermore, resting arterial blood pressure (BP; average 
of three recordings in sitting position) was also measured at baseline, and individuals 
exhibiting average BP ≥140/90 mmHg or taking antihypertensive medication(s) were 
categorized as hypertensive.  
At baseline, morning (8-10 am) fasting blood samples were obtained from all 
participants after overnight fasting (10-12 hours without food/alcohol intake, except for 
water). TG, total cholesterol (TC) and high-density lipoprotein-cholesterol (HDL-C) levels 
were measured by a chromatographic enzymatic method using a Technicon automatic 
analyzer RA-1000 [Dade Behring, Marburg, Germany; corresponding intra- and inter-assay 
coefficients of variation (CV): <4%, <9%, and <4%, respectively]. Low-density lipoprotein-
cholesterol (LDL-C) was calculated by the Friedewald formula [23]. Hypercholesterolemia 
was defined as TC >200 mg/dl or treatment with lipid-lowering drug(s). Moreover, fasting 
blood glucose (FBG) levels were measured by a Beckman glucose analyzer (Beckman 
Instruments, Fullerton, CA, USA) and subjects with FBG >125 mg/dl or on antidiabetic 
treatment were classified as having diabetes. Selected circulating pro-inflammatory 
biomarkers were also measured, namely high sensitivity C-reactive protein (CRP) by particle-
enhanced immunonephelometry (N Latex; Dade-Behring Marburg GmbH, Marburg, 
Germany; intra- and inter-assay CV: <5%), as well as tumor necrosis factor-alpha (TNF-α) 
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and interleukin-6 (IL-6) by high-sensitivity enzyme-linked immunosorbent assays (R&D 
Systems; for both assays intra- and inter-assay CV: <10%), following the corresponding 
manufacturer’s protocols. 
Finally, participants were also categorized based on the presence/absence of 
metabolic syndrome at baseline according to the harmonized metabolic syndrome definition 
[24], namely based on the presence/absence of three or more of the following criteria: (i) WC 
≥88 cm for women or ≥102 cm for men (WC cut-off values for central obesity as proposed 
by the European Cardiovascular Societies for European populations in the harmonized 
metabolic syndrome definition); (ii) TG ≥150 mg/dL (or relevant treatment); (iii) HDL-C <50 
mg/dL for women or <40 mg/dL for men (or relevant treatment); (iv) systolic BP ≥130 mm 
Hg or diastolic BP ≥85 mm Hg (or antihypertensive treatment); (v) FBG ≥100 mg/dL (or 
antidiabetic treatment). 
2.3 Lipid accumulation product (LAP) at baseline   
The LAP values at baseline were also calculated for the study participants using the 
baseline WC (cm) and TG (mmol/l) values and the LAP formulas as proposed by Kahn [9], 
namely (i) LAP for men= [WC (cm) - 65] x [TG concentration (mmol/L)]; and (ii) LAP for 
women= [WC (cm) - 58] x [TG concentration (mmol/L)]. Accordingly, the baseline LAP 
tertiles (<19, 19 – 44, >44 cm⋅mmol/L) were also extracted. 
2.4 Cardiovascular disease incidence at the 10-year follow-up (2002-2012)  
The 10-year study follow-up was conducted in 2011-2012 (median follow-up period: 
8.41 years), as previously described [25]. Briefly, 2583 of the 3042 initial participants were 
re-assessed during this follow-up [participation rate: 85%; no difference to the total study 
sample; baseline age (mean ± standard deviation; SD): 45±14 and 46±14 years for women 
and men, respectively]. As per protocol at the follow-up, study physicians obtained the 
medical records/data (WHO-ICD-10) to confirm the CVD status of each participant, 
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capturing detailed relevant data (e.g., development of myocardial infarction, angina pectoris 
and other identified forms of ischemia, as well as chronic arrhythmias, heart failure and 
stroke). For participants who died during this study follow-up, relevant data were acquired 
from death certificates and living relatives. Through this process at the 10-year study follow-
up, accurate CVD status data were obtained for 2020 participants (Table 1). In line with the 
aim of the present study to assess LAP as a potential predictor of long-term CVD risk, herein 
we present the analysis of the ATTICA study data and the documented 10-year incidence of 
fatal/non-fatal CVD of these 2020 participants in relation to the LAP at baseline. 
2.5 Statistical analysis 
Normally distributed continuous variables are presented as mean values ± SD, and 
categorical variables as frequencies. Normality was tested using the Shapiro-Wilk criterion; 
the non-normally distributed variables are presented as median and 1st, 3rd tertile. Crude, non-
fatal and fatal incidence rates of combined CVD (coronary heart disease or stroke) were 
calculated as the ratio of new CVD cases to the number of participants at the 10-year follow-
up. Associations between categorical variables were tested by the chi-square test, whereas 
between continuous variables by the Pearson r or Spearman’s rho coefficients for normally 
distributed and skewed variables, respectively. Continuous variables were tested for 
normality via P-P plots. For normally distributed variables, comparisons of means between 
participants who developed CVD and those who remained CVD-free were performed by the 
Student’s t-test, after controlling for equality of variances by the Levene’s test. For 
continuous variables without normal distribution (e.g., TG), comparisons were performed by 
the non-parametric Mann-Whitney U-test. Cox proportional hazards models were used to 
estimate the hazard ratios (HR) and the corresponding 95% confidence intervals (CI) of 
developing a CVD event during the study follow-up according to the baseline characteristics 
of participants. Kaplan-Meier curves were plotted to illustrate 10-year CVD survival by LAP 
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tertile (Log rank test was calculated to evaluate between tertiles’ comparisons). The -
2logLikelihood was also calculated to evaluate the goodness-of-fit of the estimated models. 
Moreover, ROC analysis and the corresponding Area Under the Curve (AUC; 95% CI) was 
also calculated in order to evaluate the additive value of LAP and other metabolic markers 
(e.g., TG, waist circumference, BMI) on top of known CVD risk factors (illustrated in Model 
1, Table 4). All p-values are based on two-sided tests and the corresponding 95% CI. STATA 
15 software was used for all analyses (M Psarros and Assoc., Sparti, Greece / Stata Corp 
LLC, Texas, USA). 
 
3. Results 
3.1 Baseline LAP and key cohort characteristics according to 10-year CVD incidence 
Table 1 presents key baseline characteristics of the n=2020 study participants according to 
the documented 10-year CVD status. The 10-year fatal/non-fatal CVD event rate was 157 
cases/1000 participants [n=317 participants; 119 women (118 cases/1000 participants) and 
198 men (195 cases/1000 participants); p for gender difference <0.001]. As expected, the 
group of participants who developed CVD during the 10-year study follow-up consisted 
mainly of older men, heavier smokers, and exhibited higher anthropometric indices/ratios of 
total and central obesity (BMI, WC, WHR, WHtR), compared to those who remained CVD-
free. Furthermore, this group had higher BP and FBG levels, lower MedDietScore (i.e., worse 
Mediterranean diet adherence), as well as worse profiles of circulating pro-inflammatory 
biomarkers (i.e., CRP, IL-6, TNF-α) and lipids (i.e., TC, TG, HDL-C, LDL-C) (all p-values 
<0.001; Table 1). The mean LAP value at baseline was 69% higher in the group of 
participants who developed a CVD event during the 10-year follow-up than in those who 
remained CVD-free (p <0.001, Table 1).  
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Key characteristics of the study participants according to the baseline LAP tertiles are 
presented in Table 2. The age of participants and the prevalence of hypertension, diabetes, 
hypercholesterolemia and metabolic syndrome significantly increased across the baseline 
LAP tertiles, with the participants in the lowest LAP tertile being younger and exhibiting 
lower prevalence rates of these CVD risk factors (all p-values <0.001; Table 2). In addition, 
participants in the lowest LAP tertile were mostly women, lighter smokers, more physically 
active, more adherent to the Mediterranean diet (i.e., higher MedDietScore), and had lower 
BMI, WC, WHR and WHtR (all p-values <0.001; Table 2).  
Moreover, LAP at baseline exhibited significant positive correlations to BMI, WC, 
WHR, WHtR, TG, TC, FBG, CRP, IL-6 and TNF-α levels (rho= 0.488, 0.624, 0.515, 0.075, 
0.897, 0.343, 0.281, 0.189, 0.225, and 0.221, respectively; all p-values <0.001), whereas it 
was inversely associated to HDL-C (rho= -0.318; p <0.001). All these correlations remained 
significant for both male and female participants following stratification by gender (data not 
shown).  
3.2 Baseline LAP in relationship to the 10-year CVD incidence 
Figure 1 illustrates the higher survival rate of participants in the 1st tertile of LAP as 
compared to those in the 2nd and 3rd (p for Log-rank test = 0.04; inter-tertile comparisons: p 1st 
vs. 3rd <0.001, p 1st vs. 2nd <0.001, p 2nd vs. 3rd = 0.77). Moreover, the higher rate in the decay of 
the 10-year CVD survival was observed from approximately the sixth year of study follow-
up, as expected based on the characteristics of the study's sample (relatively young adults 
without pre-existing CVD).  
The association between baseline LAP and 10-year CVD incidence was further 
evaluated through a multi-adjusted analysis that controlled for multiple CVD-related 
covariates (Table 3). Due to multicollinearity, the two variables used in the LAP formulas 
(i.e., WC, TG) were not entered together with LAP in these multi-adjusted models. At first, 
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typical demographic variables (i.e., age, sex, education), as well as certain lifestyle factors 
(i.e., smoking, physical activity, Mediterranean diet adherence) and key clinical parameters 
(i.e., hypertension, diabetes, hypercholesterolemia) that hold known associations with long-
term CVD risk were entered into Baseline Model 1 (Table 3). In the age-sex only adjusted 
model (Model 2, Table 3) LAP was significantly associated with higher 10-year CVD 
incidence. Subsequently, LAP was added into the Baseline Model 1, showing that baseline 
LAP had a significant and independent positive association with the 10-year CVD incidence, 
even after adjusting for established CVD risk factors (Model 3, Table 3). In this latter model, 
a 10-unit increase in the baseline LAP value was associated with an 11% increase of the 10-
year risk of developing CVD. Moreover, in order to test for potential mediating effects of key 
circulating pro-inflammatory biomarkers in this association between LAP and CVD, Model 3 
was additionally adjusted for CRP, IL-6 and TNF-α which were entered separately and 
consecutively, as presented in Models 4, 5, and 6, respectively (Table 3). The association 
between LAP and 10-year CVD remained significant in these models, suggesting absence of 
robust mediating effects from these circulating pro-inflammatory biomarkers. 
3.3 Predictive value of LAP on the study 10-year CVD risk against other common 
anthropometric indices/ratios of obesity 
Table 4 presents the hazard ratios (HR and corresponding 95% CI), as well as -2logL 
and AUC values of the models applied to compare the predictive value of baseline LAP on 
the 10-year CVD risk against the single components/variables of the LAP formulas (i.e., WC 
or fasting TG), as well as against the most commonly used anthropometric indices of obesity 
(i.e., models incorporating BMI, WHR, or WHtR instead of LAP). Based on these models, 
LAP exhibited better predictive value for the study 10-year CVD incidence as revealed 
through the -2logLikelihood ratio (the lower the better) and the AUC values (the higher the 
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better), than its components, i.e., WC and TG. Similarly, baseline LAP was also a better 
predictor of the 10-year CVD than BMI, WHR and WHtR (Table 4). 
 
4. Discussion 
In the 2005 study, which introduced LAP as a better index for recognizing CVD risk 
compared to BMI, Henry Kahn highlighted the need for prospective data in order to assess 
whether LAP can be a useful CVD predictor in clinical practice and cardiovascular 
epidemiology [9]. The present study addresses this still unmet need by offering new long-
term prospective data, which show that baseline LAP exhibited a significant positive 
association with the 10-year CVD incidence in a large community-based cohort of CVD-free 
Caucasian adults. Notably, this positive association remained significant even after adjusting 
for various CVD risk factors (i.e., Mediterranean diet adherence, physical activity smoking, 
hypertension, hypercholesterolemia and diabetes). Moreover, in the performed comparisons 
of the predictive value of LAP on the 10-year CVD incidence, LAP was better not only than 
each of its individual components (i.e., WC and fasting TG), but also than common 
anthropometric indices of total and central obesity (i.e., BMI, WHR and WHtR). Thus, the 
presented findings suggest that LAP may constitute a predictive marker of CVD, better than 
other classical anthropometric/metabolic CVD risk indices/ratios, but cannot be considered as 
an additive marker for CVD risk stratification. 
Since its introduction in the literature, LAP has been shown to be a powerful index for 
identifying metabolic syndrome, insulin resistance, and NAFLD in several cohorts, as well as 
a reliable marker of CVD risk in women with PCOS [10-16]. Furthermore, a retrospective 
study by Ioachimescu et al., has reported that LAP, but not BMI, can predict the all-cause 
mortality in high CVD risk, non-diabetic patients attending a preventive cardiology clinic 
[26]. Recent studies from China have also indicated that LAP is associated with increased 
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risk of intracranial atherosclerotic stenosis in middle-aged and elderly Chinese females [27], 
whilst it may be a valuable index in predicting the risk of hypertension in the Chinese 
population [28]. Moreover, in a cross-sectional study with 191 adults and elderly participants 
LAP exhibited high accuracy in visceral obesity discrimination, as assessed by the area of 
visceral adipose tissue identified by computed tomography [29]. Notably, LAP has been also 
shown to discriminate between patients with and without steatosis, although it could not 
quantitatively predict liver fat as determined quantitatively by proton magnetic resonance 
spectroscopy [30]. Further research is still needed to specifically explore the correlation 
between LAP and quantitative measures/markers of adiposity. 
Despite the increasing evidence on the direct correlation between LAP and multiple 
CVD risk factors, so far there is a paucity of data from prospective, community-based studies 
on the predictive value of LAP for long-term CVD incidence [17,18]. In this context, data 
from the prospective Tehran Lipid and Glucose Study have showed that LAP is an 
independent predictor of CVD (median follow-up: 10.1 years; 160 CVD cases during follow-
up) in 2378 CVD-free adults (57% men) with normal BMI [18]. This is in accord with our 
results on the association of LAP to the 10-year CVD incidence. However, in this Iranian 
study LAP was not superior for predicting CVD over BMI, WC, WHR and WHtR [18]. This 
apparent inconsistency with our findings may be attributed to the fact that this community-
based study included only adults with BMI <25 kg/m2, whilst other significant differences in 
the cohort characteristics of this Iranian study are also present (e.g., different ethnic 
background and higher minimum age at recruitment, since these participants were of Persian 
ancestry and at least 30 years old) [18]. 
It is noteworthy that, Després et al., first introduced the concept of the 
“hypertriglyceridemic waist” as a dichotomous cardiometabolic risk marker/indicator, which 
proved to be a good predictor of CVD outcomes and mortality [31-35]. However, obesity is a 
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continuous process rather than dichotomous, whilst both circulating TG and WC as single 
continuous variables are associated with CVD risk [9,35-37]. Thus, LAP is considered to 
expand on the concept of the hypertriglyceridemic waist by providing a continuous risk 
marker which better indicates the lipid over-accumulation in central obesity and the related 
cardiometabolic risk [9]. This related risk reflects the underlying continuous process which 
follows the excessive accumulation of visceral adipose tissue, progressively promoting 
metabolic dysregulation, atherosclerosis and low-grade inflammation [38-43]. Indeed, several 
pro-inflammatory adipokines/cytokines secreted mainly by the abdominal fat depots exert 
detrimental effects on metabolism and the cardiovascular function [41-44]. Of note, the 
significant positive association between LAP and CVD in the present study persisted even 
when the analysis was adjusted for CRP, IL-6 and TNF-α, suggesting lack of significant 
mediating effects from these circulating biomarkers which are implicated in obesity-related 
inflammation. Overall, the median CRP values observed in the ATTICA study cohort were 
similar to those generally noted in other general populations from European regions [45]. 
Further studies are required to fully elucidate the spectrum of underlying mechanisms/factors 
(e.g., dysregulated adipokine secretion and ectopic fat accumulation in the liver, skeletal 
muscles and heart) which may be implicated in the documented association between LAP and 
CVD. 
4.1 Limitations 
The present study is not without limitations. As such, it should be acknowledged that 
the baseline/entry study examination was conducted once and, hence, may be susceptible to a 
certain degree of measurement error. However, the applied study methodology is similar to 
that in other large, prospective, CVD-outcome epidemiological studies, and followed 
standardized and validated protocols/methods for collecting all study data. Thus, our findings 
can be considered reliable and generally comparable to those from studies with similar 
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cohorts. Moreover, the study cohort consisted only of Caucasians, hence the present results 
cannot be extrapolated fully to other ethnicities. Finally, due to lack of an intervention arm in 
our protocol/design, the present study cannot provide insight as to whether it is useful to 
monitor LAP as an indicator of intervention effectiveness.  
4.2 Conclusion  
The present study adds to the emerging evidence suggesting that LAP may constitute 
a simple and accurate prognostic marker of CVD risk as compared to other obesity-related 
indices/markers. Indeed, the present findings offer new prospective data suggesting that LAP 
exhibits a positive association with the 10-year CVD incidence in Caucasian 
(Mediterranean/European) adults from the general population without pre-existing CVD. 
LAP appears to be a better predictor of the long-term CVD risk than the commonly used 
anthropometric indices/ratios of total and central obesity. Future studies are still required to 
further evaluate the association between LAP and CVD in different ethnic and patient 
populations and explore whether monitoring LAP over time can be a useful indicator of the 
effectiveness of interventions against CVD. 
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Table 1. Demographic, lifestyle, behavioral and clinical characteristics of the ATTICA study participants at baseline 
based on the10-year follow-up by cardiovascular disease (CVD) status (n= 2020). 
Baseline variable Total 
  (n= 2020) 
CVD status at 10-year follow-up 
p 
    CVD-free 
     (n=1703) 
CVD 
(n= 317) 
Age (years) 45 ± 14 43 ± 13 58 ±13 <0.001 
Gender, % male 50 48 62 <0.001 
Smoking (pack years)  496 ± 501 441 ± 425 767 ± 705 <0.001 
Physical Activity, % physically active 41 40 41 0.95 
MedDietScore (range: 0-55) 26 ± 7 26 ± 6 23 ± 7 <0.001 
Body Mass Index (kg/m2) 26 ± 5 26 ± 5 28 ± 5 <0.001 
Waist circumference (cm) 90 ± 15 89 ± 15 97 ± 14 <0.001 
Waist-to-hip ratio 0.86 ± 0.1 0.85 ± 0.11 0.92 ± 0.11 <0.001 
Waist-to-height ratio 0.53 ± 0.08 0.52 ± 0.08 0.57 ± 0.07 <0.001 
Metabolic syndrome, %yes 20 18 41 <0.001 
Hypertension, %yes 30 28 51 <0.001 
Diabetes Mellitus, %yes 7  5 22 <0.001 
Hypercholesterolemia, %yes 39 40 57 <0.001 
Total cholesterol (mmol/L) 4.99±1.09 4.99±1.06 5.33±1.09 <0.001 
HDL-cholesterol (mmol/L) 1.24±0.39 1.27±0.39 1.16±0.31 <0.001 
LDL-cholesterol (mmol/L) 3.15±0.96 3.13±0.96 3.39±1.03 <0.001 
Triglycerides (mmol/L), median, tertiles 1.10, 0.77-1.60 1.09, 0.77-1.61 1.11, 0.78-1.73 <0.001 
C-reactive protein (mg/L), median, tertiles 1.02, 0.45-2.30 0.98, 0.44-2.23 1.50, 0.66-2.95 <0.001 
Interleukin-6 (pg/mL) 1.46 ± 0.55 1.43± 0.55 1.65 ± 0.51 <0.001 
Tumor necrosis factor-α (pg/mL), median, tertiles 5.77, 3.38-7.67 5.52, 3.22-7.49 7.49, 5.88-9.86 <0.001 
LAP (cm⋅mmol/L), median, tertiles 31, 19-44 30, 14-54 35, 20-61 <0.001 
Normally and non-normally distributed continuous variables are presented as mean values ± standard deviation, or median 
and 1st, 3rd tertile, respectively, and categorical variables as frequencies. p-values for the comparisons between the 10-year 
CVD-free and CVD group derived using the t-test, while for comparisons of categorical variables by the chi-square test or 
Mann-Whitney non-parametric test for variables without normal distribution (i.e., triglycerides, CRP and LAP). LAP: 
Lipid Accumulation Product; MedDietScore: validated score evaluating the Mediterranean diet adherence (higher score 
indicates better adherence) 
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Table 2. Cardiovascular disease (CVD) cases during the ATTICA study 10-year follow-up and key baseline 
characteristics of the participants (n=2020) when categorized by baseline tertiles of the Lipid Accumulation Product (LAP 
tertiles: <19; 19-44; >44cm⋅mmol/L) 
 Baseline LAP tertiles (cm⋅mmol/L; participants)   
 1st tertile 
(<19; n=660) 
2nd tertile 
(19–44; n=680) 
3rd tertile 
(>44; n=680) P 
CVD during 10-year follow-up, %yes 5 14* 25* <0.001 
Baseline characteristics     
Age (years) 36 ± 11 46 ± 13* 50 ± 13* <0.001 
Gender, % male  27 53* 67* <0.001 
Smoking (pack years) 304 ± 316 482 ± 487* 644 ± 550* <0.001 
Physical Activity, % physically active 49 40* 36* <0.001 
MedDietScore (range: 0-55) 29 ± 7.2 25 ± 5.8* 24 ± 5.9* <0.001 
Education (years of school) 13 ± 3.2 12 ± 3.7 11 ± 4.0* <0.001 
Body Mass Index (kg/m2) 23 ± 2.7 26 ± 3.4 30 ± 4.4* <0.001 
Waist circumference (cm) 76 ± 8.6 92 ± 9.1* 103 ± 13* <0.001 
Waist-to-hip ratio 0.78 ± 0.08 0.87 ± 0.08* 0.93 ± 0.10* <0.001 
Waist-to-height ratio 0.52 ± 0.05 0.54 ± 0.05 0.60 ± 0.07* 0.007 
Metabolic syndrome, %yes 1 12* 53* <0.001 
Hypertension, %yes 11 31* 46* <0.001 
Diabetes mellitus, %yes 1 3* 14* <0.001 
Hypercholesterolemia, %yes 18 43* 65* <0.001 
C-reactive protein (mg/L), median, tertiles 1.01, 1.08-2.56 1.08, 1.05-2.69* 1.80, 1.10-2.80* <0.001 
Interleukin-6 (pg/mL) 1.3 ± 0.36 1.5 ± 0.4* 1.6 ± 0.4* <0.001 
Tumor necrosis factor-α (pg/mL), median, tertiles 5.9, 2.9-4.6 6.1, 3.0-7.0* 7.8, 2.6-8.1* <0.001 
Normally and non-normally distributed continuous variables are presented as mean values ± standard deviation, or median 
and 1st, 3rd tertile, respectively, and categorical variables as frequencies. *p<0.01; p values for the between 1st vs. 2nd, 3rd 
tertile comparisons derived using the t-test, while for comparisons of categorical variables using the chi-square test, after 
correcting for the inflation of type-I error using the Bonferroni rule. MedDietScore: validated score evaluating the 
adherence to the Mediterranean diet (higher score indicates better adherence). 
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Table 3. Results from the applied Cox proportional hazard models evaluating the 10-year risk of developing a 
cardiovascular disease event (outcome) in relation to the baseline values of Lipid Accumulation Product (LAP).  
All participants  Hazard Ratios (HR)*, 95% Confidence Intervals 
 
Baseline 
Model 1 
Model 2 Model 3 Model 4 Model 5 Model 6 
Age (per 1 year) 1.06 
(1.04-1.08) 
1.08  
(1.07-1.09) 
1.06  
(1.04-1.08) 
1.06  
(1.04-1.08) 
1.05  
(1.03-1.08) 
1.06  
(1.03-1.08) 
Men vs. women 1.66 
(1.06-2.61) 
1.86 
(1.36-2.55) 
1.81  
(1.10-3.01) 
1.70  
(1.01-2.88) 
1.65 
(0.98-2.77) 
1.38  
(0.76-2.52) 
LAP (per 10 cm⋅mmol/L) - 1.04 
(1.00-1.08)‡ 
1.10 
(1.05-1.15)‡ 
1.11 
(1.04-1.19)‡ 
1.18 
(1.09-1.27)‡ 
1.21 
(1.11-1.31)‡ 
Pack-years of smoking 1.00 
(1.00-1.01) 
- 1.00  
(1.00-1.01) 
1.00  
(1.00-1.01) 
1.00  
(1.00-1.01) 
1.00  
(1.00-1.01) 
Physically active vs. inactive 0.74 
(0.49-1.11) 
- 0.75 
(0.48-1.18) 
0.79  
(0.49-1.26) 
0.80  
(0.50- 1.28) 
0.63  
(0.36-1.08) 
Education (years of school) 0.98 
(0.93-1.04) 
- 0.98  
(0.93-1.04) 
0.97  
(0.91-1.03) 
0.97  
(0.91-1.03) 
0.95  
(0.88-1.02) 
MedDietScore (range: 0-55) 0.95 
(0.92-0.99) 
- 0.97 
(0.93-1.01) 
0.96 
(0.92-1.00) 
0.96  
(0.92-0.99) 
0.97  
(0.92-1.02) 
Hypertension (y/n) 1.06 
(0.71-1.60) 
- 1.17  
(0.75-1.81) 
1.36 
(0.86-2.15) 
1.34  
(0.85-2.11) 
1.23  
(0.72-2.08) 
Diabetes mellitus (y/n) 2.39 
(1.33-4.29) 
- 2.15 
(1.11-4.18) 
1.84  
(0.91-3.74) 
1.96 
(0.97-3.93) 
2.01  
(0.87-4.67) 
Hypercholesterolemia (y/n) 1.33 
(0.90-1.97) 
- 1.43  
(0.92-2.22) 
1.34 
(0.84-2.13) 
1.35  
(0.85-2.12) 
1.45  
(0.86-2.42) 
C-reactive protein (mg/L) - - - 1.10 
(1.02-1.19) 
- - 
Interleukin-6 (pg/mL) - - - - 1.49  
(0.86-2.59) 
- 
Tumor necrosis factor-α 
(pg/mL) 
         - - - - - 1.13  
(1.05-1.22) 
* Hazard Ratios derived from semi-parametric Cox proportional hazards models. ‡ p <0.05. MedDietScore: validated 
score evaluating the adherence to the Mediterranean diet (higher score indicates better adherence).  
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Table 4. Results from the nested Cox proportional hazards models evaluating the predictive value of the Lipid Accumulation 
Product (LAP) at baseline, as well as waist circumference, fasting triglyceride levels and other commonly used 
anthropometric indices of obesity, on the 10-year cardiovascular disease event risk (outcome).  
 
Hazard 
Ratios (HR) b 
95% 
Confidence 
Intervals (CI) 
-2logLc AUC (95%CI) 
Baseline Model 1a - - 704 0.80 (0.77-0.83) 
Baseline Model 1a + LAP (per 1 cm⋅mmol/L) 1.01 (1.00-1.01) 584 0.84 (0.78-0.89) 
Baseline Model 1a + Waist circumference (per 1 cm) 1.01 (0.99-1.02) 692 0.81 (0.76-0.85) 
Baseline Model 1a + Fasting triglycerides (per 1 mg/dL) 1.00 (1.00-1.01) 592 0.82 (0.78-0.85) 
Baseline Model 1a + Body mass index (per 1 kg/m2) 1.03 (0.99-1.08) 701 0.80 (0.76-0.86) 
Baseline Model 1a + Waist-to-hip ratio (per 1 unit) 1.33  (0.18-9.98) 687 0.80 (0.74-0.86) 
Baseline Model 1a + Waist-to-height ratio (per 1 unit) 2.71 (0.21-5.45) 690 0.80 (0.76-0.83) 
a
 Baseline Model 1 included age, sex, smoking (pack years), physical activity (active/inactive), years of education, 
Mediterranean diet adherence (MedDietScore: higher score indicates better adherence), and history of hypertension, diabetes 
mellitus, and hypercholesterolemia. 
b
 Semi-parametric Cox proportional hazards models were used to calculate the hazard ratios.  
c Goodness of fit for the logistic regression models was assessed with the -2logLikelihood (the lower the better). 
AUC: Area Under the ROC Curve 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
25 
 
 
 
 
 
Figure 1. Survival curves derived from Cox proportional hazard models evaluating 10-year 
cardiovascular disease (CVD) risk by baseline Lipid Accumulation Product (LAP) tertile, in 
n=2020 participants of the ATTICA Study (p for Log-rank test = 0.04; inter-tertile 
comparisons: p 1st vs. 3rd <0.001, p 1st vs. 2nd <0.001, p 2nd vs. 3rd = 0.77). 
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Highlights 
• LAP correlates to the 10-year CVD incidence in adults without pre-existing CVD 
• LAP is associated to long-term CVD risk independently of other CVD risk factors 
• LAP is a better predictor of 10-year CVD incidence than BMI, WC, WHR and WHtR 
